Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Revive Therapeutics Ltd.
C.RVV
Alternate Symbol(s):
RVVTF
Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is...
advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:RVV)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(835)
•••
CrazyProphet
X
View Profile
View Bullboard History
Post by
CrazyProphet
on Jan 13, 2023 1:49pm
This thing wants to break
higher lets get on with it retail investors before you miss the boat
(42)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 12, 2023 9:56pm
Always live life to the fullest! Life is so unpredictable !
#Bucillamine
Fresh Insight into the Topaz Helium Project's Expected Size and Scale
posted Apr 26, 2024 9:00am by
Pulsar Helium Inc.
-
|
The prospective zone is very broad. We believe its not just an isolated occurrence but is actually something quite regionally extensive ...read more
(19)
•••
newonthestreet
X
View Profile
View Bullboard History
Comment by
newonthestreet
on Jan 12, 2023 5:03pm
RE:Facebook posts
I'm so pis$ed with this whole fiasco!!
(5)
•••
1ottrunner
X
View Profile
View Bullboard History
Post by
1ottrunner
on Jan 12, 2023 1:54pm
Facebook posts
Some cheerleading over on the fb. How great it is that the offering is fulling subscribed. So, you realized that YOU as an investor have paid to give others the benefit of free shares? That's
...more
(7)
•••
90guppy
X
View Profile
View Bullboard History
Comment by
90guppy
on Jan 12, 2023 1:34pm
RE:Update !
COOL aka DA FO-OL, very predictable your sound board stupid post. Call out mgt to not fcking f>ck up the type c meeting. that is all u need to fcking post. dont be a pos!
(42)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 12, 2023 1:31pm
Update !
# Bucillamine https://ca.finance.yahoo.com/news/revive-therapeutics-submit-updated-briefing-181500705.html
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 12, 2023 1:15pm
New Press Release - Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces it will submit an...
read article.
(7)
•••
90guppy
X
View Profile
View Bullboard History
Comment by
90guppy
on Jan 12, 2023 9:07am
RE:Revive Therapeutics Ltd. Closes $4.3 Million Offering
COOL aka da- FO-OL, just fcking call out mgt not to mess up the type c meet, that is all you have to do rather be a useless POS.
(42)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 12, 2023 6:48am
Revive Therapeutics Ltd. Closes $4.3 Million Offering
#Bucillamine https://ca.finance.yahoo.com/news/revive-therapeutics-ltd-closes-4-110000951.html
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 12, 2023 6:00am
New Press Release - Revive Therapeutics Ltd. Closes $4.3 Million Offering
TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF; FRANKFURT:31R) (“Revive” or the “Company”) is pleased to announce that it has completed the closing of its previously announced private placement (the “Offering”) by issuing a total of 28,676,064 units...
read article.
(7)
•••
90guppy
X
View Profile
View Bullboard History
Comment by
90guppy
on Jan 10, 2023 3:42pm
RE:$RVV -First-in-kind psychedelic trials treat opioid and meth
FO-OL- aka COOL call out RVV mgt to not fyck up the type c meet, this is all in the hands of mgt, everything hangs on them.
(835)
•••
CrazyProphet
X
View Profile
View Bullboard History
Post by
CrazyProphet
on Jan 10, 2023 11:56am
Looks to be under
Accumulation
(42)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 09, 2023 8:52pm
$RVV -First-in-kind psychedelic trials treat opioid and meth
#psychedelic https://news.wisc.edu/two-first-in-kind-clinical-trials-explore-psilocybin-for-substance-misuse/ Study sponsored by Revive. See “Funded Clinical Studies”. https://pharmacy.wisc
...more
(42)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 09, 2023 3:53pm
Publication Showing Bucillamine’s Potential Impact on C-19 !
#Bucillamine https://ca.finance.yahoo.com/news/revive-therapeutics-announces-publication-showing-203400945.html
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 09, 2023 3:35pm
New Press Release - Revive Therapeutics Announces Publication Showing Bucillamine's Potential Impact on COVID-19 Omicron Variants
TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces an independent...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study
Two New Contracts Awarded Covering Five Onshore Fields Producing 3,000 bbl/d of Oil
Fresh Insight into the Topaz HELIUM Project's Expected Size and Scale
Exploration company provides project portfolio update
Centurion Identifies High Quality Gold Target-Casa Berardi West Project; Acquires Additional Claims